Huntington's Disease rAAV Gene Therapy(Bayer)

N/A

Report date: 2026/05/15 20:01:45

Base Information

Drug NameHuntington's Disease rAAV Gene Therapy(Bayer)

Drug Alias NameAAVrh10.CAG.hCYP46A1AAV-CYP46A1AAV-mediated CYP46A1 gene therapy(BrainVectis)rAAVrh10.CYP46A1wtBV-101 +[7]

ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAVrh10 vector

Mechanisms of ActionCholesterol 24-hydroxylase inhibitors

TargetsCholesterol 24-hydroxylase

Therapy Area/IndicationsHuntington Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesGermanyFrance

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesAskBio Inc

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsHuntington Disease

Inactive IndicationsN/A

ATC CodeN/A